AG
BCRX icon

Aperio Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aperio Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$317K Buy
42,614
+1,606
+4% +$8.28K ﹤0.01% 2163
2020
Q3 		$141K Sell
41,008
-3,220
-7% -$13.8K ﹤0.01% 2281
2020
Q2 		$211K Buy
44,228
+26,356
+147% +$105K ﹤0.01% 2163
2020
Q1 		$36K Buy
17,872
+13
+0.1% +$36 ﹤0.01% 2288
2019
Q4 		$62K Sell
17,859
-17,687
-50% -$44.5K ﹤0.01% 2290
2019
Q3 		$102K Buy
35,546
+19,381
+120% +$60.3K ﹤0.01% 2239
2019
Q2 		$61K Sell
16,165
-4,938
-23% -$29.7K ﹤0.01% 2492
2019
Q1 		$172K Buy
21,103
+9,750
+86% +$83.5K ﹤0.01% 2188
2018
Q4 		$92K Buy
+11,353
New +$88.3K ﹤0.01% 2233

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Aperio Group's BCRX Position: Q4 2020 in Review

Aperio Group increased its BioCryst Pharmaceuticals (BCRX) stake by 3.9% in Q4 2020, buying an estimated $8.28K and bringing the position to 42,614 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #2163.

Aperio Group first reported a position in BCRX in Q4 2018 and has held it in 9 quarters since. 177 funds tracked by Wall St. Rank hold BCRX as of Q4 2020.

  • Aperio Group held 42,614 shares of BioCryst Pharmaceuticals worth $317K as of Q4 2020.
  • Aperio Group bought 1,606 BioCryst Pharmaceuticals shares in Q4 2020, an estimated $8.28K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2163 holding.
  • Aperio Group first reported a position in BioCryst Pharmaceuticals in Q4 2018 and has held it in 9 quarters since.
  • 177 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.